Synribo Omacetaxine Mepesuccinate 3.5 mg

Synribo is a prescription medicine used for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance or intolerance to two or more tyrosine kinase inhibitors (TKI). To buy Synribo or to know its price contact 3S Corporation.

Manufacturer : Teva Pharmaceuticals

Strengths available :  3.5 mg

Form :  Injection

Dosage :The recommended starting schedule for induction is 1.25 mg/m²administered subcutaneously twice daily for 14 consecutive days every 28 days, over a 28-day cycle. Cycles should be repeated every 28 days until patients achieve a hematologic response.

The recommended maintenance schedule is 1.25 mg/m²administered subcutaneously twice daily for 7 consecutive days every 28 days, over a 28-day cycle. Treatment should continue as long as patients are clinically benefiting from therapy.

Storage : Store at 20ºC to 25ºC

Is the medicine FDA  approved : Yes

Date of Approval : October 26, 2012

Common side effects are low level of platelets in the blood (thrombocytopenia),low red blood cell count (anemia), a decrease in infection-fighting white blood cells (neutropenia) which may lead to infection and fever, diarrhea, constipation, nausea, vomiting, abdominal pain, weakness, fatigue, swelling of the extremities, injection site reactions, a decrease in the number of lymphocytes in the blood (lymphopenia), weight loss, muscle pain, pain in the extremities, back pain, joint pain, headache, insomnia, cough, nosebleed, hair loss, and rash.

Pack of 1 vial